FDA approves first Neulasta biosimilar

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

FDA approved Fulphila (pegfilgrastim-jmdb) as a biosimilar to Neulasta (pegfilgrastim) to decrease the chance of infection as suggested by febrile neutropenia in patients with non-myeloid cancer who are receiving myelosuppressive chemotherapy that has a clinically significant incidence of febrile neutropenia.

To access this subscriber-only content please log in or renew you subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Login